Vontobel Holding
ALLO icon

Vontobel Holding’s Allogene Therapeutics ALLO Stock Holding History

Vontobel Holding’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.4K Sell
35,000
-27,080
-44% -$54.3K ﹤0.01% 1155
2025
Q4 		$85K Hold
62,080
– – ﹤0.01% 1377
2025
Q3 		$77K Buy
62,080
+28,080
+83% +$33.5K ﹤0.01% 1303
2025
Q2 		$38.4K Sell
34,000
-151,646
-82% -$202K ﹤0.01% 1242
2025
Q1 		$271K Sell
185,646
-9,811
-5% -$18.5K ﹤0.01% 925
2024
Q4 		$416K Buy
195,457
+173,457
+788% +$428K ﹤0.01% 840
2024
Q3 		$61.6K Hold
22,000
– – ﹤0.01% 1053
2024
Q2 		$51.3K Buy
22,000
+4,000
+22% +$11.8K ﹤0.01% 1040
2024
Q1 		$80.5K Hold
18,000
– – ﹤0.01% 1035
2023
Q4 		$57.8K Buy
18,000
+4,000
+29% +$11.3K ﹤0.01% 1065
2023
Q3 		$44.4K Hold
14,000
– – ﹤0.01% 1045
2023
Q2 		$69.6K Sell
14,000
-10,000
-42% -$54.1K ﹤0.01% 1063
2023
Q1 		$119K Hold
24,000
– – ﹤0.01% 1018
2022
Q4 		$151K Sell
24,000
-89,711
-79% -$831K ﹤0.01% 1014
2022
Q3 		$1.23M Buy
113,711
+4,067
+4% +$55.3K 0.01% 502
2022
Q2 		$1.25M Buy
+109,644
New +$973K 0.01% 490

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vontobel Holding's ALLO Position: Q1 2026 in Review

Vontobel Holding reduced its Allogene Therapeutics (ALLO) stake by 44% in Q1 2026, selling an estimated $54.3K and leaving 35,000 shares worth $85.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1155.

Vontobel Holding first reported a position in ALLO in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.25M in Q2 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Vontobel Holding held 35,000 shares of Allogene Therapeutics worth $85.4K as of Q1 2026.
  • Vontobel Holding sold 27,080 Allogene Therapeutics shares in Q1 2026, an estimated $54.3K.
  • Allogene Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #1155 holding.
  • Vontobel Holding first reported a position in Allogene Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Vontobel Holding's Allogene Therapeutics position peaked at $1.25M in Q2 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.